At the time of filing this report, the stock of the Bangalore-based company was trading at Rs 240.10 apiece on the BSE, down ...
Solid earnings, robust biosimilars growth, and improving margins drive renewed optimism; analysts see double-digit upside ...
Biocon (BIOS) delivered lower-than-expected financial performance for the quarter. Temporary constraints in the biologics and CRDMO segments impacted revenue for the quarter. Re-prioritization of high ...
Biocon: Nuvama said Q4FY26 growth moderated as Biocon upgraded facilities to scale up capacity in response to anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results